Abstract
The use of Wilms’ tumor 1 (WT1) immunotherapy is considered to be an innovative approach for the treatment of malignant gliomas. Because of its novelty, tools that can accurately predict response to this therapy are still lacking. In this article, we investigated the role of WT1 protein expression level (score 1–4) and MIB-1 staining index in predicting survival outcome after therapy in patients with recurrent or progressive glioblastoma multiforme. Tumor samples from 37 patients enrolled in a phase II clinical trial on WT1 immunotherapy were immunohistochemically analyzed for WT1 levels and MIB-1 index. Results showed that median progression-free survival (PFS) was longer in the WT1 high expression group (score 3 and 4) compared with that of the low expression group (score 1 and 2) (20.0 weeks vs. 8.0 weeks; P = 0.022), and that the median overall survival (OS) was likewise longer in the former compared to the latter group (54.4 weeks vs. 28.4 weeks; P = 0.035). Furthermore, within the WT1 high expression group, tumors with intermediate staining intensity (WT1 score 3) have both the longest median PFS and OS, 24.4 weeks and 69.4 weeks, respectively. On the other hand, no significant correlation was noted between MIB-1 staining index and survival. In conclusion, our study has shown that WT1 protein expression level, not MIB-1 staining index, can be used as a prognostic marker to foretell outcome after immunotherapy, and that patients whose tumors have intermediate WT1 expression have the best survival outcome.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Clark AJ, Dos Santos WG, Mccready J, et al (2007) Wilms tumor 1 expression in malignant gliomas and correlation of 1KTS isoforms with p53 status. J Neurosurg 107:586–592
Menssen HD, Bertelmann E, Bartelt S, et al (2000) Wilms’ tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens. J Cancer Res Clin Oncol 126:226–232
Izumoto S, Tsuboi A, Oka Y, et al (2008) Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:963–971
Therasse P, Arbuck SG, Eisenhauer EA, et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Institute 92:205–216
Coppes MJ, Campbell CE, Williams BRG (1993) The role of WT1 in Wilms tumorigenesis. FASEB J 7:886–895
Oka Y, Udaka K, Tsuboi A, et al (2000) Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. J Immunol 164:1873–1880
Sugiyama H (2002) Cancer immunotherapy targeting WT1 protein. Int J Hematol 76:127–132
Inoue K, Ogawa H, Sonoda Y, et al (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405–1412
Loeb DM, Evron E, Patel CB, et al (2001) Wilms’ tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumorspecific promoter methylation. Cancer Res 61:921–925
Oji Y, Miyoshi S, Maeda H, et al (2002) Overexpression of the Wilms’ tumor gene WT1 in de novo lung cancers. Int J Cancer 100:297–303
Campbell CE, Kuriyan NP, Rackley RR, et al (1998) Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma. Int J Cancer 78:182–188
Ueda T, Oji Y, Naka N, et al (2003) Overexpression of the Wilms’ tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci 94:271–276
Oka Y, Tsuboi A, Oji Y, et al (2008) WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20:211–220
Cheever MA, Allison JP, Ferris AS, et al (2009) The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337
Hashiba T, Izumoto S, Hashimoto N, et al (2007) Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med Chir (Tokyo) 47:165–170
Stupp R, Mason WP, van den Bent MJ, et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Tsuboi A, Oka Y, Ogawa H, et al (2000) Cytotoxic T-lymphocyte responses elicited to Wilms’ tumor gene WT1 product by DNA vaccination. J Clin Immunol 20:195–202
Moskowitz S, Jin T, Prayson R (2006) Role of MIB1 in predicting survival in patients with glioblastomas. J Neuro-Oncol 76:193–200
Vaquero J, Zurita M, Morales C, et al (2000) Prognostic significance of endothelial surface score and MIB-1 labeling index in glioblastoma. J Neuro-Oncol 46:11–16
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chiba, Y., Hashimoto, N., Tsuboi, A. et al. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. Brain Tumor Pathol 27, 29–34 (2010). https://doi.org/10.1007/s10014-010-0265-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10014-010-0265-9